Regulus Therapeutics (NASDAQ:RGLS) Releases Quarterly Earnings Results, Meets Expectations

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20), Zacks reports. During the same period in the prior year, the business posted ($0.40) earnings per share.

Regulus Therapeutics Stock Down 7.4 %

Shares of RGLS traded down $0.11 during midday trading on Monday, reaching $1.37. 148,346 shares of the stock were exchanged, compared to its average volume of 520,572. The stock's 50 day simple moving average is $1.28 and its 200 day simple moving average is $1.46. Regulus Therapeutics has a twelve month low of $0.83 and a twelve month high of $3.00. The company has a market cap of $89.74 million, a P/E ratio of -1.28 and a beta of 1.42.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RGLS shares. Canaccord Genuity Group reaffirmed a "buy" rating and set a $28.00 price target on shares of Regulus Therapeutics in a report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a report on Friday. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $12.75.

Remove Ads

Insider Activity at Regulus Therapeutics

In related news, CEO Joseph P. Hagan acquired 50,000 shares of the company's stock in a transaction on Thursday, January 30th. The stock was purchased at an average cost of $1.09 per share, with a total value of $54,500.00. Following the acquisition, the chief executive officer now directly owns 260,808 shares of the company's stock, valued at approximately $284,280.72. The trade was a 23.72 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Christopher Ray Aker sold 38,547 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the sale, the vice president now owns 54,634 shares of the company's stock, valued at approximately $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 223,998 shares of company stock worth $282,237. Corporate insiders own 4.35% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.